Physician profile
Kai Zhang
NPI 1366737314
$9,781.40
in general payments reported to CMS, 2019-2025
32 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $2,011 · 2023: $2,613 · 2024: $2,566 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,267 · Education: $97.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,266.85 |
| Education | $97.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,416.41 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,054.79 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Amneal Pharmaceuticals LLC | $756.57 | 2022-2025 | Rytary, Ongentys, Crexont |
| Neurocrine Biosciences, INC. | $555.68 | 2022-2025 | Ongentys, Ingrezza |
| Mdd US Operations, LLC | $449.88 | 2022-2025 | Gocovri |
| Pfizer INC. | $391.33 | 2023-2025 | |
| Gilead Sciences, INC. | $311.68 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $299.00 | 2023-2025 | Qelbree, Qelbree |
| Merz Pharmaceuticals, LLC | $272.27 | 2025 | Inbrija, Xeomin |
| Intercept Pharmaceuticals, INC. | $250.00 | 2022 | |
| Acadia Pharmaceuticals INC | $242.20 | 2022-2025 | Nuplazid |
| Lundbeck LLC | $201.06 | 2022-2023 | Vyepti |
| Sk Life Science, INC. | $163.94 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $162.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $150.00 | 2024 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $142.82 | 2023-2024 | Nuedexta, Rexulti |
| Kyowa Kirin, INC. | $130.94 | 2023-2024 | Nourianz |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.00 | 2023 | |
| Argenx US, INC. | $71.84 | 2022-2024 | Vyvgart Hytrulo |
| Eisai INC. | $67.71 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $58.23 | 2022 | |
| Neurelis, INC. | $53.99 | 2025 | Valtoco |
| Stryker Corporation | $42.44 | 2025 | Xpress Loprofile, Core, Clarifix |
| Lilly USA, LLC | $27.27 | 2022 | |
| Ucb, INC. | $23.77 | 2022 | |
| Grifols USA, LLC | $23.20 | 2025 | Gamunex-C |
| Alnylam Pharmaceuticals INC. | $22.63 | 2022 | |
| Axsome Therapeutics, INC. | $22.31 | 2025 | Symbravo |
| Octapharma USA, INC. | $20.34 | 2023 | Octagam Immune Globulin (Human) |
| Amarin Pharma, INC. | $19.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.